Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy
© Ivan G. Shabalin et al. 2020..
Dexamethasone, a widely used corticosteroid, has recently been reported as the first drug to increase the survival chances of patients with severe COVID-19. Therapeutic agents, including dexamethasone, are mostly transported through the body by binding to serum albumin. Here, the first structure of serum albumin in complex with dexamethasone is reported. Dexamethasone binds to drug site 7, which is also the binding site for commonly used nonsteroidal anti-inflammatory drugs and testosterone, suggesting potentially problematic binding competition. This study bridges structural findings with an analysis of publicly available clinical data from Wuhan and suggests that an adjustment of the dexamethasone regimen should be further investigated as a strategy for patients affected by two major COVID-19 risk factors: low albumin levels and diabetes.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
IUCrJ - 7(2020), Pt 6 vom: 29. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shabalin, Ivan G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Albumin |
|---|
| Anmerkungen: |
Date Revised 22.02.2024 published: Print-Electronic UpdateOf: bioRxiv. 2020 Jul 23;:. - PMID 32743572 Citation Status Publisher |
|---|
| doi: |
10.1107/S2052252520012944 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316332836 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316332836 | ||
| 003 | DE-627 | ||
| 005 | 20240229142918.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1107/S2052252520012944 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM316332836 | ||
| 035 | |a (NLM)33063792 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shabalin, Ivan G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: bioRxiv. 2020 Jul 23;:. - PMID 32743572 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © Ivan G. Shabalin et al. 2020. | ||
| 520 | |a Dexamethasone, a widely used corticosteroid, has recently been reported as the first drug to increase the survival chances of patients with severe COVID-19. Therapeutic agents, including dexamethasone, are mostly transported through the body by binding to serum albumin. Here, the first structure of serum albumin in complex with dexamethasone is reported. Dexamethasone binds to drug site 7, which is also the binding site for commonly used nonsteroidal anti-inflammatory drugs and testosterone, suggesting potentially problematic binding competition. This study bridges structural findings with an analysis of publicly available clinical data from Wuhan and suggests that an adjustment of the dexamethasone regimen should be further investigated as a strategy for patients affected by two major COVID-19 risk factors: low albumin levels and diabetes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a albumin | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a drug transport | |
| 700 | 1 | |a Czub, Mateusz P |e verfasserin |4 aut | |
| 700 | 1 | |a Majorek, Karolina A |e verfasserin |4 aut | |
| 700 | 1 | |a Brzezinski, Dariusz |e verfasserin |4 aut | |
| 700 | 1 | |a Grabowski, Marek |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Panasiuk, Mateusz |e verfasserin |4 aut | |
| 700 | 1 | |a Chruszcz, Maksymilian |e verfasserin |4 aut | |
| 700 | 1 | |a Minor, Wladek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t IUCrJ |d 2014 |g 7(2020), Pt 6 vom: 29. Sept. |w (DE-627)NLM240540468 |x 2052-2525 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2020 |g number:Pt 6 |g day:29 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1107/S2052252520012944 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2020 |e Pt 6 |b 29 |c 09 | ||